Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A; Cefepime Study Group,. Zanetti G, et al. Among authors: lew d. Antimicrob Agents Chemother. 2003 Nov;47(11):3442-7. doi: 10.1128/AAC.47.11.3442-3447.2003. Antimicrob Agents Chemother. 2003. PMID: 14576100 Free PMC article. Clinical Trial.
Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.
Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, Schaad U, Herter C, Eggimann P, Huber O, et al. Cometta A, et al. Among authors: lew d. Antimicrob Agents Chemother. 1994 Jun;38(6):1309-13. doi: 10.1128/AAC.38.6.1309. Antimicrob Agents Chemother. 1994. PMID: 8092830 Free PMC article. Clinical Trial.
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A. Jaccard C, et al. Among authors: lew d. Antimicrob Agents Chemother. 1998 Nov;42(11):2966-72. doi: 10.1128/AAC.42.11.2966. Antimicrob Agents Chemother. 1998. PMID: 9797234 Free PMC article. Clinical Trial.
Pyomyositis as a nontropical disease.
Harbarth SJ, Lew DP. Harbarth SJ, et al. Among authors: lew dp. Curr Clin Top Infect Dis. 1997;17:37-50. Curr Clin Top Infect Dis. 1997. PMID: 9189660 Review. No abstract available.
Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.
Huttner A, Von Dach E, Renzoni A, Huttner BD, Affaticati M, Pagani L, Daali Y, Pugin J, Karmime A, Fathi M, Lew D, Harbarth S. Huttner A, et al. Among authors: lew d. Int J Antimicrob Agents. 2015 Apr;45(4):385-92. doi: 10.1016/j.ijantimicag.2014.12.017. Epub 2015 Jan 19. Int J Antimicrob Agents. 2015. PMID: 25656151
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.
Schrenzel J, Harbarth S, Schockmel G, Genné D, Bregenzer T, Flueckiger U, Petignat C, Jacobs F, Francioli P, Zimmerli W, Lew DP; Swiss Staphylococcal Study Group. Schrenzel J, et al. Among authors: lew dp. Clin Infect Dis. 2004 Nov 1;39(9):1285-92. doi: 10.1086/424506. Epub 2004 Oct 11. Clin Infect Dis. 2004. PMID: 15494904 Clinical Trial.
High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.
Uçkay I, Bernard L, Buzzi M, Harbarth S, François P, Huggler E, Ferry T, Schrenzel J, Renzoni A, Vaudaux P, Lew DP. Uçkay I, et al. Antimicrob Agents Chemother. 2012 Mar;56(3):1258-64. doi: 10.1128/AAC.05808-11. Epub 2011 Dec 12. Antimicrob Agents Chemother. 2012. PMID: 22155824 Free PMC article.
804 results